Plasma N-glycans in colorectal cancer risk.
Plasma N-glycans in colorectal cancer risk.
复制标题
DOI:
10.1038/s41598-018-26805-7
复制
发表时间:
2018-06-05
影响因子:
4.6
通讯作者:
Rudd PM
中科院分区:
文献类型:
--
作者:
Doherty M;Theodoratou E;Walsh I;Adamczyk B;Stöckmann H;Agakov F;Timofeeva M;Trbojević-Akmačić I;Vučković F;Duffy F;McManus CA;Farrington SM;Dunlop MG;Perola M;Lauc G;Campbell H;Rudd PM
Aberrant glycosylation has been associated with a number of diseases including cancer. Our aim was to elucidate changes in whole plasma N-glycosylation between colorectal cancer (CRC) cases and controls in one of the largest cohorts of its kind. A set of 633 CRC patients and 478 age and gender matched controls was analysed. Additionally, patients were stratified into four CRC stages. Moreover, N-glycan analysis was carried out in plasma of 40 patients collected prior to the initial diagnosis of CRC. Statistically significant differences were observed in the plasma N-glycome at all stages of CRC, this included a highly significant decrease in relation to the core fucosylated bi-antennary glycans F(6)A2G2 and F(6)A2G2S(6)1 (P < 0.0009). Stage 1 showed a unique biomarker signature compared to stages 2, 3 and 4. There were indications that at risk groups could be identified from the glycome (retrospective AUC = 0.77 and prospective AUC = 0.65). N-glycome biomarkers related to the pathogenic progress of the disease would be a considerable asset in a clinical setting and it could enable novel therapeutics to be developed to target the disease in patients at risk of progression.
登录
查看更多内容
影响因子:
64.5
作者:
Dennis JW;Nabi IR;Demetriou M
通讯作者:
Demetriou M
影响因子:
--
作者:
Ercan, Altan;Barnes, Michael G.;Nigrovic, Peter A.
通讯作者:
Nigrovic, Peter A.
影响因子:
5.5
作者:
Collins, Emily S.;Galligan, Marie C.;FitzGerald, Oliver
通讯作者:
FitzGerald, Oliver
影响因子:
4.4
作者:
Hamfjord, Julian;Saldova, Radka;Kure, Elin H.
通讯作者:
Kure, Elin H.
影响因子:
2
作者:
Croce, MV;Sálice, VC;Segal-Eiras, A
通讯作者:
Segal-Eiras, A